CXCR4 and neoplasm: Therefore, a study that designed CXCR4-targeted lipid-coated poly lactic-co-glycolic acid (PLGA) nanoparticles of sorafenib modified with AMD3100 (ADOPSor-NPs) for targeted delivery of sorafenib to HCC, discovered that ADOPSor-NPs specifically deliver sorafenib to HCC, blocking CXCR4/SDF1α, and restrict M2 polarization and TAMs infiltration [122,123]; therefore, hindering tumor progression and improving overall survival in an in situ HCC mouse model.